Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumor, B-Raf Mutation-Related Tumors

In brief

The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors

Key facts

Study ID

NCT04249843

Run by

MapKure, LLC

People needed

109

Starts

2020-02-17

Expected to finish

2025-08-04

Last updated by the study team

2025-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars Sinai Medical Center — Beverly Hills, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• MD Anderson — Houston, Texas, United States
• University of Virginia Comprehensive Cancer Centre — Charlottesville, Virginia, United States
• Blacktown Hospital — Blacktown, New South Wales, Australia
• The Kinghorn Cancer Centre, St Vincent Hospital Sydney — Sydney, New South Wales, Australia
• One Clinical Research — Nedlands, Perth, Australia
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.